Skip to main content
TTrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor.
RECRUITINGPhase 2INTERVENTIONAL

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Long-term Extension Study for Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) in JNJ-81201887 Parent Clinical Studies

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

The purpose of this study is to assess the long-term safety and tolerability after an intravitreal injection (a shot of medicine into the eye) of JNJ-81201887 administered in parent clinical studies.

Who May Be Eligible (Plain English)

Who May Qualify: - Participants who were enrolled and received treatment with JNJ-81201887 or sham in a parent clinical study (81201887MDG2001, 81201887MDG1003) - Females (women of childbearing potential), male participants, and partners of male participants will not be required to use contraception in this LTE study - Must sign an willing to sign a consent form form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study. The ICF may be signed by an impartial witness and/or legally designated representative depending on national/local regulations Who Should NOT Join This Trial: - There are no exclusion criteria for this LTE study Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Participants who were enrolled and received treatment with JNJ-81201887 or sham in a parent clinical study (81201887MDG2001, 81201887MDG1003) * Females (women of childbearing potential), male participants, and partners of male participants will not be required to use contraception in this LTE study * Must sign an informed consent form (ICF) indicating that participant understands the purpose of, and procedures required for, the study and is willing to participate in the study. The ICF may be signed by an impartial witness and/or legally designated representative depending on national/local regulations Exclusion Criteria: * There are no exclusion criteria for this LTE study

Treatments Being Tested

DRUG

JNJ-81201887

No study intervention will be administered as part of this LTE study.

OTHER

Sham Procedure

No study intervention will be administered as part of this LTE study.

Locations (20)

Retina Associates Southwest PC
Tucson, Arizona, United States
Retina Consultants of Orange County
Fullerton, California, United States
Shiley Eye Institute Jacobs Retina Center
La Jolla, California, United States
California Retina Consultants
Oxnard, California, United States
California Eye Medical Specialists
Pasadena, California, United States
Retina Consultants San Diego
Poway, California, United States
Bay Area Retina Associates
Walnut Creek, California, United States
Retina Group of Florida
Fort Lauderdale, Florida, United States
VitreoRetinal Associates, PA
Gainesville, Florida, United States
Retina Specialty Institute
Pensacola, Florida, United States
Retina Vitreous Associates of Florida
St. Petersburg, Florida, United States
Georgia Retina
Marietta, Georgia, United States
Marietta Eye Clinic
Marietta, Georgia, United States
University Retina
Lemont, Illinois, United States
Midwest Eye Institute
Carmel, Indiana, United States
Maine Eye Center
Portland, Maine, United States
Retina Specialists
Baltimore, Maryland, United States
The Retina Group of Washington
Chevy Chase, Maryland, United States
Cumberland Valley Retina Consultants
Hagerstown, Maryland, United States
Ophthalmic Consultants of Boston
Boston, Massachusetts, United States